Intelligence · Clinical Development
Pipeline search results
Programs matching “chemotherapy” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 127 pipeline programs matching "chemotherapy" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
ALDESLEUKIN for Germ Cell Tumors refractory to salvage chemotherapy
The George Institute
Germ Cell Tumors refractory to salvage chemotherapy
1 trial -
APHP190205
Pari Pharma GmbH
PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II STUDY INCORPORATING DARATUMUMAB TO CHEMOTHERAPY AND STEM CELL TRANSPLANTATION
1 trial -
Avatrombopag
Hospital Authority, Hong Kong
Chemotherapy-induced Thrombocytopenia
1 trial -
B-MAD chemotherapy
Takeda
Extranodal NK/T-cell Lymphoma
1 trial -
Blinatumomab plus Reduced-dose Chemotherapy
The First People's Hospital of Lianyungang
Precursor B-Cell Acute Lymphoblastic Leukemia
1 trial -
CMBG453B12206B
Novartis Pharmaceuticals
intermediate, high or very high risk MDS in adult patients chronic Myelomonocytic Leukemia - 2 (CMML-2) Acute Myeloid Leukemia (AML) in adult patients unfit for chemotherapy
1 trial -
CSET N° 2020/3188
The George Institute
Patients with hormone-receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-negative) advanced breast cancer (ABC) who have already received standard therapy for HR+/HER2-negative ABC, including only one line of chemotherapy for advanced/metastatic disease.
1 trial -
Chemotherapy + immunotherapy
Hunan Province Tumor Hospital
Non Small Cell Lung Cancer
1 trial -
Chemotherapy plus apatinib
Lei Li
Recurrent Cervical Carcinoma
1 trial -
Chemotherapy+PD-1 inhibitor+8Gy x 3f
Xiyuan Hospital of China Academy of Chinese Medical Sciences
HR+HER2- Breast Cancer
1 trial -
Chidamide + Tislelizumab + chemotherapy (CapeOX )
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Colon Adenocarcinoma
1 trial -
D798MC00002
AstraZeneca AB
Sub-study 5: Unresectable Pleural Mesothelioma (Volrustomig Monotherapy), Sub-study 4: Esophageal Squamous Cell Carcinoma (Volrustomig in Combination with Chemotherapy).
1 trial -
EBVALLO
Pierre Fabre Medicament
EBV+ primary imunodeficiency lymphoproliferative disease (LPD), EBV+ post-transplant LPD where standard first line therapy (rituximab or chemotherapy) is inappropriate, including CD20-negative disease, EBV+ sarcomas, including leiomyosarcoma, or smooth muscle tumors, EBV+ associated post-transplant LPD involving the central nervous system (EBV+ CNS PTLD)
1 trial -
ET-20-049
Lacuna Pharma Pty Ltd
Patiens with locally advanced/metastatic endometrial carcinoma or cervix carcinoma progressing/relapsing after at least one prior systemic chemotherapy.
1 trial -
Eltrombopag
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Chemotherapy-induced Thrombocytopenia
1 trial -
Forxiga 10 mg film-coated tablets
Fondazione Telethon ETS
Chemotherapy-induced cardiotoxicity in breast cancer
1 trial -
Fruquintinib Combined With Chemotherapy
Takeda
Metastatic Colorectal Cancer (CRC)
1 trial -
Furmonertinib in combination with Anrotinib and chemotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lung Cancer (NSCLC)
1 trial -
GADOTERIC ACID, [18F]fludarabine
Pari Pharma GmbH
Patients with newly diagnosed primary central nervous system lymphoma naïve to surgery, radiotherapy or chemotherapy
1 trial -
GRANISETRON EXTENDED RELEASE INJECTION (GERSC)
Heron Therapeutics
Chemotherapy-induced Nausea and Vomiting
1 trial -
Halneuron
Dogwood Therapeutics
Chemotherapy Induced Neuropathic Pain
1 trial -
Herombopag
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Chemotherapy-induced Thrombocytopenia
1 trial -
Hypofractionated radiation/chemotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer
1 trial -
IMFINZI 50 mg/mL concentrate for solution for infusion.
Ningbo Cancer Hospital
Patients with metastatic breast cancer in 1st or 2nd line of chemotherapy
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.